Trump's order looking to cut prescription drug prices is bearish for drug stocks at the surface, but is the worst already priced in?

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

U.S. equities were mixed at midday, with tech shares and a better-than-expected consumer inflation report lifting the S&P 500 ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Eli Lilly’s stock jumped 3.44% on May 12, ending the day at $759.83, and leaving investors mildly thrilled. This surge placed ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Indian Pharma stocks were on a strong uptrend today, with the Nifty Pharma index rising by 1.19% in intraday trade.

Live Updates Live Coverage Has Ended What Sectors are Winning & Losing Today 11:28 am by Markets remain up today with the ...

Companies showing rapid sales growth and improving profit margins include Eli Lilly, Micron, AMD and Newmont Every quarter during earnings season it can be useful to see which companies have improved ...

In an executive order Monday morning, Trump announced plans to reduce drug prices by 30 to 80%.

President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide. Trump said drug prices ...